Hennepin Life Sciences

About Hennepin Life Sciences

Hennepin Life Sciences (HLS) was established in 2009 and is a clinical-stage biotechnology company focused on identifying and developing broad spectrum antimicrobial therapeutics to address the challenges associated with antibiotic resistance. The company is advancing its novel antimicrobial, GML Gel, for local administration to prevent and treat CA-UTIs caused by ESKAPE pathogens in hospitals and long-term care centers. HLS has several antimicrobial technologies in its pipeline including products to treat skin and soft tissue infections and vaginal candidiasis.
YEAR FOUNDED:
2009
LEADERSHIP:
Founder and CSO: Patrick M. Schlievert
CEO: Thomas Burke
CLINICAL TRIAL:
Please click here for clinical trial information.